Research and Practice in Thrombosis and Haemostasis

Papers
(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Navigating the inevitable: artificial intelligence and the future of scientific communication87
Intraindividual variability of von Willebrand factor and the need for repeated testing66
Promise and pitfalls of viscoelastic testing for assessing blood hemostasis in ultraendurance sports62
Contemporary trends in maternal outcomes during delivery hospitalizations among pregnancies complicated by von Willebrand disease—a cross-sectional analysis59
Acquired von Willebrand syndrome in children51
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach50
Corrigendum to ‘Optimizing care for patients after major anticoagulant-related bleeding: a narrative review and proposal for a clinical care pathway’44
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates43
Exploration of biomarkers for inhibitor development in persons with hemophilia A40
Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia40
Accumulating evidence for direct oral anticoagulants in liver disease38
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA)37
PB1140 Laboratory Features and Genotype of a Family with Heritable Dysfibrinogenaemia (HD)36
PB0403 A Common Variant in GRK5 Reveals a PAR1-Specific Regulation in Platelets36
PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic34
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec33
PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina31
PB1031 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study29
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA28
OC 45.3 Major Bleeding Event Rates in Patients on Hemodialysis and Peritoneal Dialysis: Results from the International DOPPS and PDOPPS28
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia28
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)28
OC 74.1 Circulating Biomarkers and Mortality in Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke Study28
PB0308 Anticoagulation Monitoring of UFH (Unfractioned Heparin) in a Pediatric Patient during Long Term ECMO (Extracorporeal Membrane Oxygenation)26
OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study26
PB0249 Some Coagulation Profiles (PT, APTT, TT, FIB), Red Cell, Total White Cell, Platelet Counts and Their Indices Activity Levels in Persons Exposed to Wood Smoke (Firewood) in Calabar, Nigeria26
1.1873650550842